In order to accelerate the development of safe, effective and affordable vaccines, EVI is committed to advance the establishment of a European vaccine R&D infrastructure, an initiative that is currently supported by the European Commission (EC) in the context of TRANSVAC2. TRANSVAC2 builds upon the success of TRANSVAC, the European Network of Vaccine Research and Development funded under the EC´s previous Framework Programme (FP7). TRANSVAC made significant contributions to the European vaccine development landscape, providing scientific-technical services to more than 29 vaccine projects and developing a roadmap for the establishment of a sustainable European vaccine R&D.